Trial · NCT03982134
PDR001 + Panobinostat for Melanoma and NSCLC
NCT03982134, Phase 1, Withdrawn, Muhammad Furqan
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PDR001 + Panobinostat for Melanoma and NSCLC. Trials, record NCT03982134. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03982134
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PDR001 + Panobinostat for Melanoma and NSCLC
- NCT number
- NCT03982134
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Muhammad Furqan
- Conditions
- Melanoma, Non Small Cell Lung Cancer
- Interventions
- PDR001, Panobinostat
- First posted
- 2019-06-11
- Last updated
- 2019-10-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the safety and tolerability of PDR001 in combination with panobinostat in determining a recommended Phase II dose | Initiation of treatment up to 2 years | The recommended Phase 2 dose will be determined by using a 3 + 3 design with 1 dose escalation and 2 dose deescalation cohorts. Safety assessments will consist of monitoring and recording all adverse events, including serious adverse events, the monitoring of hematology, chemistry, ECG and the regular monitoring of vital signs, thyroid function, pregnancy and physical exam including weight and performance status. |
| Secondary | Incidence of dose limiting toxicities (DLTs) using CTCAE, Version 5.0 | Initiation of treatment up to 2 years | All adverse events (AEs) will be considered in DLT assessment unless the event is clearly unrelated to trial treatment. The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 will be used. |
| Secondary | Progression free survival (PFS) per RECIST 1.1 | Initiation of treatment up to 2 years | PFS is defined as the time between the first dose of study therapy and the earliest date of progression or death (participants who have neither progressed nor dies will be censored at the most recent last-known-alive date). |
| Secondary | Overall survival (OS) | Initiation of treatment up to 2 years | OS is calculated from time when study therapy begins to death from any cause. |
| Secondary | Overall Response Rate (ORR) per RECIST 1.1 | Initiation of treatment up to 2 years | OS is defined as the time between the first dose of study therapy and death (participants who have not died will be censored at the most recent last-known-alive date). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03982134
GET https://conductscience.org/api/trials/v1/NCT03982134/registered